Bristol Myers Squibb (NYSE:BMY) (NYSE: BMY) is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. With roots tracing back to the founding of Bristol-Myers in 1887 and E.R. Squibb & Sons in 1858, the company merged in 1989 to combine decades of expertise in pharmaceutical research and development. Today, Bristol Myers Squibb concentrates on four therapeutic areas—oncology, hematology, immunology and cardiovascular disease—seeking to address unmet medical needs through both small molecules and biologics.
The company’s product portfolio includes leading therapies such as the immuno-oncology agents Opdivo and Yervoy, the blood cancer therapy Revlimid, the rheumatoid arthritis treatment Orencia, and the cardiovascular medicine Eliquis. In addition to its marketed drugs, Bristol Myers Squibb maintains a robust pipeline of clinical and preclinical candidates in areas like fibrosis, neuroscience and cell therapy. Research efforts are supported by collaborations with academic institutions and biotech partners, reflecting a commitment to science-driven innovation.
Bristol Myers Squibb operates in more than 60 countries, with major research hubs in North America, Europe and Asia, and manufacturing facilities across key regions. The company’s global footprint enables it to serve diverse patient populations and navigate complex regulatory environments. Through its network of subsidiaries and joint ventures, Bristol Myers Squibb also strives to improve patient access to therapies in emerging markets and under-resourced communities.
Under the leadership of Chairman and Chief Executive Officer Giovanni Caforio, M.D., Bristol Myers Squibb emphasizes strong corporate governance, sustainability and social responsibility. The executive team and board of directors oversee strategic initiatives aimed at enhancing research productivity, driving operational efficiency and fostering a culture of inclusivity and ethical conduct within the organization.
